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Background/aim: Available information on the radiological findings of the 2019 novel coronavirus disease (COVID-19) is constantly
updated. Ground glass opacities (GGOs) and consolidation with bilateral and peripheral distribution have been reported as the most
common CT findings, but less typical features can also be identified. According to the reported studies, SARS-CoV-2 infection is not
limited to the respiratory system, and it can also affect other organs. Renal dysfunction, gastrointestinal complications, liver dysfunction,
cardiac manifestations, and neurological abnormalities are among the reported extrapulmonary features. This review aims to provide
updated information for radiologists and all clinicians to better understand the radiological manifestations of COVID-19.
Materials and methods: Radiological findings observed in SARS-CoV-2 virus infections were explored in detail in PubMed and Google
Scholar databases.
Results: The typical pulmonary manifestations of COVID-19 pneumonia were determined as GGOs and accompanying consolidations
that primarily involve the periphery of the bilateral lower lobes. The most common extrapulmonary findings were increased resistance
to flow in the kidneys, thickening of vascular walls, fatty liver, pancreas, and heart inflammation findings. However, these findings were
not specific and significantly overlapped those caused by other viral diseases, and therefore alternative diagnoses should be considered
in patients with negative diagnostic tests.
Conclusion: Radiological imaging plays a supportive role in the care of patients with COVID-19. Both clinicians and radiologists
need to know associated pulmonary and extrapulmonary findings and imaging features to help diagnose and manage the possible
complications of the disease at an early stage. They should also be familiar with CT findings in patients with COVID-19 since the disease
can be incidentally detected during imaging performed with other indications.
Key words: COVID-19, imaging, computed tomography, signs, extrapulmonary involvement

1. Introduction
Coronavirus disease (COVID-19) is an infectious disease
caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2). After COVID-19 was first reported
in Wuhan, China, in December 2019, it spread rapidly
worldwide and was declared a pandemic by the World
Health Organization (WHO) on March 12, 2020 [1].
The SARS-CoV-2 virus has had devastating effects on
human life, health systems, and economies. SARS-CoV-2
is a beta-coronavirus that infected more than 167 million
people as of June 2021, resulting in more than 3 million
deaths worldwide. A significant proportion of those with
COVID-19 infection remain asymptomatic (40%–50%)
or show relatively mild symptoms (40%) [2]. COVID-19
disease caused by SARS-CoV-2 typically presents with
weakness, fever, cough, and sore throat but can progress
to pneumonia, bronchitis, and acute respiratory distress
syndrome (ARDS). However, since none of these
symptoms are specific to COVID-19, and the disease can

rapidly progress to severe pneumonia, multiple organ
involvement including renal failure, vascular thrombosis,
ischemia, respiratory distress, and gastrointestinal
symptoms, there is an urgent need for rapid diagnostic
tests [3]. Although the reverse transcriptase-polymerase
chain reaction (RT-PCR) test for viral nucleic acids is the
gold standard in the diagnosis of COVID-19, radiological
imaging, especially computed tomography (CT) has
become increasingly important in diagnosis due to the
false-negative results of the RT-PCR test [4]. Studies have
shown that the sensitivity of CT is between 60% and 98%
[5,6]. This range is relatively higher compared to the RTPCR test (60%–70%), but its specificity (25%–53%) is low.
The positive and negative predictive values of chest CT for
COVID-19 are estimated at 92% and 42%, respectively. The
relatively low negative predictive value reduces the value of
CT as a screening test for COVID-19 in the early stages
of the disease [7]. In addition, considering that it contains
ionizing radiation, CT should be used as a problem-solving
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method in patients with a negative RT-PCR test rather
than as a screening method [8]. Imaging plays an essential
role in the management of COVID-19. In this study, we
aimed to review the areas of use and imaging findings of
various imaging methods, such as chest radiographs, CT,
and ultrasonography in the diagnosis and treatment of
COVID-19.
2. Thoracic imaging in COVID-19
2.1. Chest radiography
Chest radiography is often the first imaging modality of
choice for patients with known or suspected COVID-19
pneumonia. In the literature, the diagnostic value of
chest X-ray in COVID-19 pneumonia is reported to vary
between 30% and 60%, which is relatively low. Although it
is possible to detect some abnormalities in the presence of
viral pneumonia on chest X-ray, normal findings obtained
from this modality do not exclude the disease. Moreover, if
the disease progresses, the possibility of an abnormal chest
radiograph increases [7,9,10].
Chest radiography often does not show any abnormality
in the early stage of COVID-19 infection. Therefore,
radiography has not been recommended as a first-line
method for the investigation of chest abnormalities in
patients with suspected COVID-19 [11]. However, in
mild COVID-19 conditions, chest radiography may
demonstrate local irregular radiopacities in the outer parts
of the lungs and the subpleural region [12]. COVID-19
lung involvement occurs in bilateral involvement of the
peripheral and lower lobe basal segments [13]. In severe
cases, there is a widespread, sometimes patchy, multiple
consolidation with a small amount of pleural effusion. In
critically ill patients, areas of consolidation covering the
entire lung are referred to as white lung [14].
In conclusion, the diagnostic contribution of chest
radiography is lower than that of chest CT, and noncontrast
chest CT should be considered for the early diagnosis
of viral disease in suspected patients with normal chest
radiography findings [10].
2.2. Ultrasonography (USG)
USG is one of the most commonly used imaging methods
in clinical practice and allows for the systematic and rapid
examination of multiple organs at the bedside without
using radiation. The general opinion is that USG cannot
detect lung lesions; however, many lung pathologies can
be imaged with this modality. The main signs of lung
ultrasound in COVID-19 can be defined as A-lines, B-lines,
subpleural consolidation, and lung deviation signs [15]. In
COVID-19-infected cases, the occurrence of pulmonary
lesions predominantly in the peripheral regions of the
lung and the subpleural areas of both lungs facilitates
sonographic imaging [16]. However, deeply located lung
lesions cannot be detected on USG, and it is difficult to
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use this imaging method in the differential diagnosis of
pneumonia. USG is not recommended in the diagnosis
of mild cases but it can be considered as an additional
pulmonary and cardiac evaluation method, especially in
critically ill patients who should not be moved and for
whom a CT examination is not possible [17].
USG is particularly important in examining critically
ill patients and determining treatments, particularly
hemodynamic therapy. It is helpful in functional imaging
rather than anatomical imaging, and its applications can
be summarized as follows [18,19]:
First, USG is an imaging method that offers the rapid
evaluation of the disease. An increase in the number of
B-lines and the area of consolidation may indicate lung
disease progression [20]. Second, respiratory support is
required in severe and critical cases, but the time point
for the transition from noninvasive ventilation to invasive
mechanical ventilation is essential [21]. Lung USG showing
progressive diffuse B-lines and significantly increased
diaphragm activity may indicate severe lung damage. When
mechanical ventilation cannot improve oxygenation,
extracorporeal membrane oxygenation (ECMO) may be
a treatment option. USG provides visual management
in the ECMO process [22]. Third, echocardiography
(cardiac ultrasound) can be used to evaluate circulatory
functions. The most frequently reported complication in
critically ill patients with COVID-19 is ARDS, followed
by acute heart damage and secondary infection [23].
Echocardiography can also quickly assess hemodynamics
and determine whether there are segmental wall motion
abnormalities, stress-induced cardiomyopathy, or acute
right heart dysfunction that may guide treatment [24,25].
Finally, coagulation abnormalities have been reported
in approximately 20% of critically ill COVID-19 cases
[23,26]. Sudden worsening of the condition often suggests
a state of hypercoagulation with a dramatic increase in the
D-dimer level [27]. Asymmetrical pain or swelling may
indicate the risk of lower extremity deep vein thrombosis
(DVT) for patients staying in bed for more than three
days. For patients with central venous catheters, local
swelling of catheterized limbs may indicate the risk of
upper limb DVT. In all these cases, vascular structures
can be evaluated with color Doppler USG [28]. In this
way, effective and timely interventions can be provided for
patients at high risk of embolism [12].
The main limitation of USG is that in general it has
poor specificity, and its findings overlap with those of
other pneumonia etiologies or incidental chronic findings
(e.g., chronic heart failure or pulmonary fibrosis)[29].
2.3. Chest CT
CT is sensitive the early signs of COVID-19 and changes
that may not be seen on chest radiography [30]. It is
essential to know that in 50% of patients with COVID-19
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symptoms, an abnormal chest CT finding may be
expected in the first days after symptoms appear [13].
On the contrary, lung changes due to COVID-19 can be
monitored on CT in patients with no symptoms and are
usually seen incidentally.
Chest CT can have characteristic features of COVID-19
during active infection, and therefore it can help monitor
the course of the disease and provide timely treatment.
The hallmark of COVID-19 is the bilateral presence of
patchy GGOs that can merge into dense, consolidative
lesions with a predominantly peripheral distribution in
the subpleural areas, as well as bronchovascular bundles
[31,32]. As the disease progresses, the number of lesions
can rapidly increase and extend into central regions [33].
During the recovery of the disease, lesions gradually
regress over two weeks, during which time fibrotic changes
may occur [34]. In addition to GGOs and consolidations,
many other CT findings, such as interstitial thickening,
halo sign, inverted halo sign, and airway-vascular changes
can be seen in COVID-19 pneumonia. These findings and
distribution patterns may help distinguish COVID-19
pneumonia from other types of pneumonia [35].
2.3.1. Ground glass opacities (GGOs)
GGOs are nonspecific findings defined as hazy lung
opacities that do not cover the underlying vascular or
bronchial boundaries and are assumed to be related to
partial airspace filling or interstitial thickening (Figure 1)
[36]. The predominant CT pattern in COVID-19 is bilateral
GGOs associated with consolidations, but findings may
differ from patient to patient or depending on the stage
of the disease [31,32]. It has been reported that GGOs are
seen at a rate of 50%–95%, and they are isolated in 50%
of cases and accompanied by consolidations in 30%–40%
[37–39].
2.3.2. Consolidations
Consolidations result from the complete displacement of
alveolar air spaces by pathological fluids or cells, leading
to an increase in parenchymal density that obscures the
underlying vessels and bronchial walls [36]. Consolidations
have been reported in 20%–63% of cases and may be
multifocal, irregular, or segmental with subpleural or
peribronchovascular distribution [40,41]. Consolidations
occur with the progression of the disease within two weeks
after the onset of the disease and often accompany GGOs
[42].
2.3.3. Reticular opacity
The reticular pattern consists of a complex network of linear
opacities associated with interlobular and intralobular
septal thickening and is caused by lymphocyte infiltration
(Figure 2) [36,43,44]. With an incidence of 27%, it is the
third most common finding in COVID-19 after GGOs and
consolidations [40,42,45], and its incidence increases over
the course of the disease [42].

Figure 1. A 35-year-old male COVID-19 patient presenting fever
and headache for four days. CT scan shows pure ground-glass
opacities in bilateral multilobe (arrows).

2.3.4. Crazy paving pattern
This pattern is defined as the presence of GGOs with
overlapping interlobular septal thickening, giving the
appearance of irregular cobblestones and may be associated
with alveolar edema combined with the inflammation of
interstitial structures [36]. In COVID-19, this finding is
less frequent than GGOs and consolidations alone [34].
However, this sign has been reported in 5%–36% of patients
and may be considered an indication of progression or the
highest stage of the disease when accompanied by GGOs
and consolidations [41].
2.3.5. Air bronchograms
Air bronchograms, in which air-filled bronchi can be seen
in a highly attenuated parenchymal background, have
been recorded in series of patients affected by COVID-19
(Figure 3) [36,45]. However, some autopsy studies indicate
that the bronchi are actually filled with gelatinous mucus
plugs; therefore, the term bronchiolectasis may be more
appropriate than air bronchogram because the bronchi are
not filled with air and are associated with mild bronchial
dilatation [46]. Similar studies have also emphasized that
the high viscosity of mucus can cause bronchiolar damage,
and thus lead to bronchiolectasis and characteristic dry
cough in patients with COVID-19 [35].
2.3.6. Airway changes
Airway changes reported in association with COVID-19
occur as a result of bronchiectasis in some patients and
bronchial wall thickening in 10%–20% of cases [5,40,41].
The pathological mechanism is bronchial obstruction and
inflammatory damage of the bronchial wall, both of which
lead to the destruction of the bronchial wall structure and
development of fibrosis, and consequently bronchiectasis
[36]. In addition, the percentage of bronchial wall
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Figure 2. A 66-year-old male COVID-19 patient presenting
fever with cough for seven days. Multiple ground-glass opacities
and consolidation with a thickened intralobular and interlobular
septum (arrows).

Figure 3. A 66-year-old female COVID-19 patient presenting
fever with cough for nine days. The air bronchogram sign in right
lower lobe (frame).

thickening has been determined to be significantly higher
in patients with critical COVID-19 [41].
2.3.7. Pleural changes
The most common pleural change in patients with
COVID-19 is not pleural effusion (5%) but pleural
thickening (32%) [42]. The presence of pleural thickening
was confirmed by autopsy findings [46]. The presence of
pleural effusion has been suggested to be a poor prognostic
factor [41,42].
2.3.8. Subpleural lines
Subpleural lines refer to thin curvilinear opacities of
approximately 1–3 mm in thickness, located in the
subpleural region and distributed parallel to the pleural
surface (Figure 4). They are a nonspecific sign seen
in 33% of COVID-19 cases, but they may also result
from atelectasis, pulmonary edema, and fibrosis [47].
In addition, subpleural lines may be associated with the
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Figure 4. A 49-year-old female COVID-19 patient presenting
chest pain for 14 days. Subpleural lines (black arrows) with
thickened intralobular and interlobular septums (blue arrows).

predominantly peripheral location of parenchymal changes
in COVID-19 [48].
2.3.9. Fibrosis
Fibrotic lesions may occur in patients with the proliferative
disease and those recovering from chronic pulmonary
inflammation due to the replacement of cellular components
by scar tissue [49]. Fibrosis is usually seen at two to three
weeks after the onset of COVID-19 when interstitial changes
begin to occur [50]. Some studies have suggested that the
presence of fibrosis indicates advanced COVID-19, which
can lead to bronchial deformation. However, the general
belief is that fibrosis is a part of the recovery process [51,52].
2.3.10. Nodules
A pulmonary nodule is defined as a round or irregular
parenchymal opacity of less than 3 cm in diameter and often
associated with the presence of viral pneumonia [36,52].
Multiple solid nodules with irregular contours have been
found in 3%–13% of patients with COVID-19, sometimes
accompanied by a halo sign [34,53].
2.3.11. Halo sign
This is described as a nodule or mass surrounded by
GGOs [36]. The pathological mechanism underlying this
sign remains unclear. However, apart from perilesional
hemorrhage being a possible sign of viral infections and
organized pneumonia, the halo sign has also been associated
with angioinvasive fungal infections or hypervascular
metastases [54,55].
2.3.12. Reversed halo sign
The presence of a ring-like consolidation zone with an
overlapping circular GGO is defined as an inverted
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halo sign (Figure 5) [36], which has been reported to be
associated with COVID-19. It is considered as a healing
lesion with a low-density core or a new lesion that develops
around a preexisting GGO [56,57]. In addition, it has
been previously described in association with cryptogenic
organizing pneumonia and other pulmonary infections
[58,59].
2.3.13. Vascular changes
The dilation of the pulmonary vessels can be caused by
proinflammatory factors resulting in capillary wall damage
and edema. The onset of the disease can occur in as early
as one to seven days [51].
2.3.14. Cavitation and air bubble sign
Cavitation is extremely rare in patients with COVID-19
[60]. The air bubble sign, defined as the small aircontaining areas associated with bronchiolectasis, is also
uncommon but can be seen in COVID-19 cases (Figure
6) [61].
2.3.15. Lymphadenopathy
When the short-axis diameter of the mediastinal lymph
node is more than 1 cm, it is defined as lymphadenopathy
[36]. This finding has been reported in 4%–8% of patients
with COVID-19 and considered to be an essential
risk factor for severe pneumonia [40–42]. However,
bacterial superinfection should be suspected when
lymphadenopathies are accompanied by pleural effusion
and small lung nodules [38,62,63].
2.3.16. Pericardial effusion
Pericardial effusion has been reported in approximately 5%
of patients with COVID-19 and assumed to be associated
with the presence of severe inflammation [40,41].
2.4. Differential diagnosis
CT showing high sensitivity (97%) but poor specificity
(25%) for the diagnosis of COVID-19 has been primarily
attributed to the COVID-19 pneumonia findings
overlapping those of other viral types of pneumonia,
especially influenza viruses, parainfluenza virus,
adenovirus, and respiratory syncytial virus [64–66].
Similar to COVID-19, most viral types of pneumonia have
a predominant distribution in the posterior and peripheral
parts of the lungs, affecting more than one lung lobe.
However, some findings may be useful in the differential
diagnosis. For example, the main feature of pneumonia
caused by the respiratory syncytial virus is small
centrilobular nodules and consolidation areas, usually
distributed asymmetrically in the lungs. Adenovirus
pneumonia on chest CT shows bilateral multifocal GGOs
with irregular consolidations and may have a lobar or
segmental distribution. In parainfluenza virus pneumonia,
the presence of centrilobular nodules with bronchial wall
thickening may help distinguish it from other viral types
of pneumonia [33].

Figure 5. A 48-year-old male COVID-19 patient presenting
fever for five days CT scan shows a reversed halo sign (central
ground-glass opacity surrounded by denser consolidation of
crescentic shape) in left lower lobe (frame).

Figure 6. A 49-year-old male COVID-19 patient presenting
fever with diarrhea for three days. The air bubble sign (frame)
with GGO and consolidation in the right inferior lobe.

The radiological appearance of COVID-19 is not much
different from pneumonia associated with the other two
coronaviruses, SARS and MERS, possibly because they
belong to the same family of Coronaviridae, and they have
similar underlying pathological features. However, unlike
the reported SARS cases, COVID-19 pneumonia shows
a multifocal tendency of distribution and a peripheral
distribution of GGOs in the upper lobes and a basilar or
subpleural preference in the lower lobes.
The consolidation frequency and severity score of
COVID-19 pneumonia are also much lower than SARS,
which may explain the lower mortality rates of the
former. The more peripheral distribution of COVID-19
pneumonia in the upper lobes can be used to distinguish
it from MERS [67]. In contrast to COVID-19 pneumonia,
SARS and MERS pneumonia usually have a single
focus, and no reference to halo or reverse halo signs has
been made in the literature [68]. Furthermore, unlike
COVID-19, neither SARS nor MERS has been associated
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with the findings of lymphadenopathy, pleural effusion, or
nodules [67].
The CT features of COVID-19 also show some
similarities with other pulmonary pathologies, such as
pulmonary edema, pulmonary hemorrhage, bronchiolitis
obliterans, chronic obstructive pulmonary disease, and
drug-induced lung disease [66]. In pulmonary edema,
chest CT displays GGOs with central distribution, usually
associated with smooth interlobular septal thickening,
pleural effusion, and cardiomegaly, indicating congestive
heart failure. In diffuse pulmonary hemorrhage, CT
usually reveals patchy or diffuse GGOs associated with
consolidations or poorly defined centrilobular opacities
[69]. Air trapping is the main CT feature in bronchiolitis,
while bronchial wall thickening, bronchiectasis, and
centrilobular opacities can also be seen. In chronic
obstructive pulmonary disease, bronchial wall thickening
can be seen in addition to pulmonary emphysema.
Drug-induced lung diseases are very diverse and can
show various lung presentations ranging from ARDS
to pulmonary fibrosis. For example, the most common
chest CT features in methotrexate-induced lung disease
are diffuse parenchymal opacification, reticular opacities,
and centrilobular nodules with a pattern of nonspecific
interstitial pneumonia [66].
Since COVID-19 can show similar clinical and
radiological features with many lung pathologies, it is
essential to be aware of the characteristic findings of the
disease in both clinical and imaging to determine its
severity, predict its prognosis, and perform a differential
diagnosis.
3. COVID-19 and extrapulmonary radiological findings
Although the respiratory spread of COVID-19 is well
documented in the literature, it has also been shown that
the virus is not limited to the lungs [70]. There are many
studies on the extrapulmonary involvement of COVID-19,
and it is accepted that some of these involvements can
seriously affect the disease prognosis [71]. It is considered
that SARS-CoV-2 uses angiotensin-converting enzyme 2
(ACE2) as the cell receptor for cellular access in humans
[72]. ACE2 receptor is highly expressed in the lungs,
kidneys, testicles, gastrointestinal system (GIS), liver,
vascular endothelial cells, and arterial smooth muscle cells
[73]. Therefore, all these organs and systems with a high
expression of ACE2 receptors can be considered to be the
targets of SARS-CoV-2 infection [74].
3.1. Genitourinary system (GUS) involvement
Kidneys are one of the most frequently affected
extrapulmonary organs in patients infected with SARSCoV-2, especially in severe cases [75–77]. The etiology of
kidney dysfunction associated with COVID-19 disease
is probably multifactorial [78]. The SARS-CoV-2 virus
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may have a direct cytopathic effect on kidney tissue or
cause damage through systemic inflammatory response
syndrome, cytokine release, and sepsis, as observed in other
viral diseases. Renal cell damage can cause tubular atrophy,
renal interstitial fibrosis, and acute kidney injury (AKI),
which is strongly associated with increased mortality and
morbidity [79]. Studies conducted with patients affected by
COVID-19 have shown that AKI is mainly characterized
by tubular injury, increased serum creatinine and ureanitrogen concentrations [80,81]. The severity of tubular
damage is also higher in patients with severe COVID-19
than in those less affected by the disease.
CT imaging findings in patients with AKI include
inflammation and edema of the renal parenchyma
characterized by lower CT attenuation values than

normal
kidneys (Figure 7). In addition, multiple wedge-shaped
parenchymal defects compatible with infarction can be seen
[82,83]. Increased parenchymal echogenicity, loss of cortexmedulla separation, and thickening of the collecting system
wall can also be seen in renal USG.
A significant increase in the resistive index value (above
0.9) on the color Doppler USG examination indicates
tubular damage. However, similar changes due to rejection
can be seen in kidney transplant patients. In these cases, if
clinical findings do not allow for a differential diagnosis, a
renal biopsy is required [84–86].
Since ACE2 is produced in testicular cells, it plays a
critical role in fertility. Therefore, due to potential testicular
damage caused by the virus, infertility can be seen as one
of the late complications of the disease. Additionally, viral
orchitis may occur [87].
3.2. Cardiovascular system involvement
Cardiac involvement in COVID-19 disease may be due to the
direct invasion of the myocardium. However, it may also be
secondary to a hyperinflammatory condition, which results
in atherosclerotic plaques becoming prone to rupture. As a
result, endothelial dysfunction and increased procoagulant
activity increase the risk of thromboembolism. In addition,
40% of patients requiring hospitalization due to COVID-19
have cardiovascular disease, which may worsen due to
COVID-19 involvement [88,89].
Myocarditis is among the major complications of SARSCoV-2 infection, accounting for 7% of deaths associated
with COVID-19 [90]. In the echocardiography of patients
infected with COVID-19, half of the patients show
ventricular abnormalities, mainly ventricular dysfunction
patterns, myocardial infarction, and signs of myocarditis
[91]. Right ventricular abnormalities are common in those
with the more severe disease [90]. Other findings include
global or regional myocardial systolic dysfunction with
or without pericardial effusion [88,89]. Right ventricular
abnormalities have been reported in these patients,
also reflecting the presence of severe respiratory illness,
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Figure 7. A 39-year-old female COVID-19 patient presenting
with cough, fever for five days, and increased creatinine levels. CT
scan shows the increased size in the transplanted kidney (white
arrow) and increased density consistent with inflammation in the
perirenal fatty tissue (blue arrow).

Figure 8. A 30-year-old male COVID-19 patient presenting with
abdominal pain. CT scan shows volume increase in the pancreas
(white arrow) and increased density in the surrounding fatty
tissue (blue arrow), consistent with pancreatitis.

including subclinical or clinical thromboembolism [91].
CT coronary angiography can help rule out coronary
artery disease in all these cases. It is also used to
differentiate the pathologies of nonobstructive coronary
artery myocardial infarction, cardiomyopathy, and acute
myocarditis [91]. Cardiac magnetic resonance imaging
(MRI) is an ideal imaging method in the diagnosis of
acute myocarditis. Cardiac involvement has been detected
in 78% of those who have had COVID-19 and undergone
cardiac MRI, while ongoing myocardial inflammation
is reported to be as high as 60% [92]. Imaging findings
in these patients are abnormal T1 and T2 signals and
late contrast enhancement indicating regional damage
due to myocardial inflammation. The majority of high
T2 signals are associated with myocardial edema in the
interventricular septum and the anterior and anterolateral
walls [93].
3.3. Peripheral vascular system involvement
Vascular involvement in COVID-19 infection may not
be limited to the cardiovascular system. This disease can
cause a transient state of hypercoagulation, resulting in the
development of vascular thromboembolic events, such as
deep vein thrombosis and pulmonary embolism if proper
medication is not administered [94–96]. Although the exact
pathogenesis of COVID-19-associated hypercoagulopathy
remains unclear, high D-dimer levels and coagulation
abnormalities have been reported in patients with the
disease. These findings have been associated with a poor
clinical course and higher mortality rate [97–100].
3.4. Gastrointestinal system (GIS) involvement
GIS symptoms are common in COVID-19 and may be
present in up to 26% of patients. GIS symptoms usually

occur one to two days after pulmonary symptoms and
include anorexia (26.8%), nausea and vomiting (10.2%),
diarrhea (12.5%), and abdominal pain (9.2%) [101,102].
GIS symptoms can sometimes be seen at an early stage
of the disease, preceding the other typical symptoms of
COVID-19 [103].
The spectrum of cross-sectional imaging findings
of intestinal pathologies in patients with COVID-19
ranges from inflammation to ischemia and necrosis.
Imaging findings include intestinal wall thickening,
contrast enhancement changes in the intestinal wall,
ileus, pneumatosis, and gas in the portal venous system
[101,104–106].
3.5. Hepatobiliary system involvement
COVID-19 involvement of the liver, gall bladder, pancreas,
and spleen has also been described. In liver injury
associated with SARS-CoV-2, increased parenchymal
echogenicity and decreased parenchymal density can be
seen on the CT examination due to hepatic steatosis [104].
Infarcts may occur in the spleen, which can be visualized
as wedge-shaped, low-density areas on CT [107]. Examples
of pathologies in the gall bladder and tracts of COVID-19
cases are distension of the gallbladder, thickening of the
bladder wall, and sludge formation without intraluminal
stones [108]. Concerning the pancreas, an increase in
the pancreas volume can be seen, indicating pancreatitis
without stones in the biliary tract (Figure 8) [109]. USG or
CT can easily detect the presence of these findings.
3.6. Nervous system involvement
Approximately one-quarter of patients with COVID-19
have some form of neurological pathology [110]. In
hospitalized patients, the rate of neurological complications
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varies between 6 and 36%, with acute cerebrovascular
diseases being the most common and serious [111].
The most common symptoms are altered mental states,
focal deficits, and seizures due to ischemic stroke [112].
Other nonspecific clinical symptoms include headache,
confusion, and dizziness. Loss of smell and taste in the
early stages of COVID-19 disease occurs in approximately
15% of patients [113]. Most patients with neurological
involvement have at least one preexisting comorbidity,
such as cardiovascular disease and diabetes [112].
Nervous system imaging findings associated
with COVID-19 disease can be categorized as
follows: cerebrovascular disorder, encephalitis, other
encephalopathies, and peripheral nervous system
abnormalities. Cerebrovascular disease may refer to the
presence of large or small vessel ischemic infarction or
hemorrhagic infarction due to venous sinus thrombosis,
as well as microhemorrhages involving the juxtacortical
and callosal white matter or gross hemorrhage [114].
Encephalitis is diagnosed based on cortical FLAIR signal
abnormality regardless of diffusion imaging feature.
Although some publications indicate that medial temporal
lobe involvement is more common, there is no consensus
on this issue [115]. In addition, there may be an abnormal
leptomeningeal enhancement in encephalitis, which is
sometimes only seen in the postcontrast FLAIR sequence
[116]. Depending on encephalitis, differences in signal
and enhancement and diffusion abnormalities can also be
seen in the basal ganglia, especially the substantia nigra,
globus pallidus, and striatonigral pathways [113].
Another form of neurological involvement seen in
COVID-19
is diffuse leukoencephalopathy characterized
x̄
by symmetrical and multifocal hyperintense lesions in
the supratentorial white matter and diffusion restriction
in which the juxtacortical white matter is partially
preserved. Sometimes the lesions can be hemorrhagic
[114,116]. These findings, possibly due to hypoxia, are
seen in critically ill patients receiving long-term ventilator
support and associated with increased mortality [117].
Acute necrotizing encephalopathy, which is included in
some case reports and considered to be caused by the
cytokine storm, is among the neurological complications.
This type of involvement is characterized by rim-shaped
symmetrical hemorrhagic lesions in the thalamus, medial
temporal lobe, and subinsular region [118]. Widespread
brainstem involvement may also be seen. Similar findings

have been reported in patients with COVID-19 presenting
with hypoxic-ischemic encephalopathy or posterior
reversible encephalopathy syndrome [112].
In patients with anosmia, abnormal hyperintensity
and enhancement may be seen in the olfactory bulbus and
gyrus rectus, despite imaging findings being completely
normal in the early stage of the disease [119]. Lastly, in
Guillain–Barré syndrome associated with SARS-CoV-2,
enhancement can be seen in the caudal nerve roots [120].
4. Conclusion
Radiological imaging plays a supportive role in the care
of patients with COVID-19. Imaging findings are very
diverse, and depending on the stage of the disease, their
frequency and distribution vary. Comprehensive studies
on the imaging of COVID-19 pneumonia emphasize the
importance of CT, although other imaging methods can
also be used to diagnose and treat COVID-19 infection.
Pulmonary magnetic resonance imaging is not typically
considered among the first-line modalities in investigating
suspected lower respiratory tract infections, but it may be
a viable alternative for patient groups where excessive or
repeated exposure to ionizing radiation should be avoided.
COVID-19 pneumonia progresses with bilateral
GGOs, primarily distributed in the peripheral parts of the
lower lung lobes and often accompanying consolidations
on CT scans. However, these findings are not specific and
significantly overlap those related to the other causes of
viral pneumonia, and alternative diagnoses should be
considered in patients with negative diagnostic tests.
The respiratory tract is the primary system affected
by COVID-19, but the cardiovascular system, GIS,
hepatobiliary system, GUS, and the nervous system
can also show signs and symptoms associated with
COVID-19. Therefore, both clinicians and radiologists
need to know the extrapulmonary findings and imaging
features of COVID-19 to help diagnose and manage the
possible complications of the disease in an early stage.
They should also be familiar with CT findings that can
be seen in patients with COVID-19 since the disease can
be incidentally detected during imaging performed with
other indications.
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